Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCT... ( LEXINGTON Mass. Aug. 13 /- Indevu...)

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

Date:8/13/2008

LEXINGTON, Mass., Aug. 13 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc.

The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025.

In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States. Allergan and Indevus launched SANCTURA XR in the U.S. in January 2008. Indevus licensed to Rottapharm Madaus Group the right to market SANCTURA XR in certain territories outside the U.S., except in Canada, Japan, Korea and China, where the Company and Rottapharm Madaus have joint rights. In May 2008, Indevus and Rottapharm Madaus licensed rights to market SANCTURA XR in Canada to Allergan.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
2. Indevus Announces Allergan as New Partner for SANCTURA Brand
3. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
4. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
5. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
6. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
9. Indevus Announces Management Changes
10. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
11. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008

Post Your Comments:

(Date:6/18/2013)... -- RegeneCure announced today the start ... Bone Regeneration (GBR) Dental Membrane as a bone stimulating aid ... encountered when patients have a tooth replaced with a dental ... the implant. Consequently there is often a need to support ... regenerates. The bone substitute material, in turn, needs to be ...

(Date:6/18/2013)... June 18, 2013 The "Bioinformatics Market By ... Knowledge Management Tools & Data Analysis Services) & Application (Genomics, ... the Major Market Drivers, Restraints, and Opportunities in ... Asia-Pacific and Rest of World. ... 22 Figures 364 ...

(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering. ...

(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...

Breaking Biology Technology:RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2 RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3 Bioinformatics Market Worth $7.5 Billion by 2017 2 Bioinformatics Market Worth $7.5 Billion by 2017 3 Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2 Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3 Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2 Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3

[0] RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants [0] Bioinformatics Market Worth $7.5 Billion by 2017 [0] Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 [0] Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc.

... Eastern Time -, SAN FRANCISCO, Nov. 10 ... corporate progress and financial,results for the quarter ended September ... of significant,achievement and progress and was capped with the ... collaboration not only gives us,access to a world-class partner ...

... Conference Call Today To Discuss the Data and Ongoing ... Clinical Development Programs, ... announced today top-line data from its,SB-509-601 clinical trial, one of Sangamo,s ... SB-509 for diabetic,neuropathy (DN). The data demonstrate that repeat administration of ...

... Divestitures of Non-Core Product Lines -, HOPKINTON, ... CALP ) today reported third quarter financial,results ... line divestitures: the,sale of its AutoTrace(R) product line ... of its Pharmaceutical Development and Quality Analysis,(PDQ) product ...

Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs

(Date:6/18/2013)... DNA and this modification can occur in millions ... scientists believed that this epigenetic phenomenon actively reduced ... of researchers from the University of Geneva (UNIGE), ... the Faculty of Medicine, reveals that this is ... may play both a passive and active role ...

(Date:6/17/2013)... in patients with severe brain infections in Vietnam. Further ... responsible for the symptoms of disease. , The virus ... 644 patients with severe brain infections in the study, ... the 122 patients with non-infectious brain disorders that were ... system are often fatal and patients who do survive, ...

(Date:6/17/2013)... improving original foundations with more modern elements. Using this ... Kenneth P. Dietrich School of Arts and Sciences have ... delivery, gas storage, and gas transport more efficient and ... the latest issue of the Journal of the ... recent work builds upon Pitt Associate Professor of Chemistry ...

Breaking Biology News(10 mins):The secret of DNA methylation 2 New virus isolated from patients with severe brain infections 2 New virus isolated from patients with severe brain infections 3 'Chemical architects' build materials with potential applications in drug delivery and gas storage 2

[0] The secret of DNA methylation [0] New virus isolated from patients with severe brain infections [0] 'Chemical architects' build materials with potential applications in drug delivery and gas storage

... relatedness of an animal food protein to a human protein ... by scientists from the Institute of Food Research in Norwich ... proteins have the potential to become allergens, but the study ... to act as allergens depends on their evolutionary distance from ...

... pathway that plays a critical role in the growth ... important insight into the development of the vascular system ... inhibiting the blood vessels that fuel cancers, diabetic eye ... published online on Oct. 14 in Nature Genetics. was ...

... 2007Today at the Prostate Cancer Foundations Annual Scientific Retreat, ... foods such as tomatoes and fish, maintaining a healthy ... help prevent prostate cancer, and help men live healthier ... will be diagnosed with prostate cancer in their lifetime, ...

Cached Biology News:Animal food allergens unmasked 2 Study reveals a key to blood vessel growth and possible drug target 2 Study reveals a key to blood vessel growth and possible drug target 3 Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 2 Leading researchers to reveal comprehensive dos and don'ts for prostate cancer 3

Animal food allergens unmasked Study reveals a key to blood vessel growth and possible drug target Leading researchers to reveal comprehensive dos and don'ts for prostate cancer

Blue Standard is 3-cyano-7-hydroxycoumarin....

Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...

6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...

Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....

Biology Products:

Fluorescent Standards Blue Standard from Invitrogen Fluorescent Standards Cyan Standard from Invitrogen 6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE) from Molecular Probes (Invitrogen)Rabbit Anti-Human ECE1 Polyclonal Antibody, Unconjugated from Atlas Antibodies